Medicinal chemistry and therapeutic potential of CpG DNA

Trends in Molecular Medicine

Volumn 8, Issue 3, 2002, Pages 114-121

  Agrawal, Sudhir ^a   Kandimalla, Ekambar R ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BCG VACCINE; DNA; TUMOR ANTIGEN; VACCINE;

ALLERGY; ASTHMA; CANCER; CPG ISLAND; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION; REVIEW;

5' FLANKING REGION; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS; CPG ISLANDS; DNA; HUMANS; IMMUNOTHERAPY; INFECTION; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM BOVIS BCG;

EID: 0036090792     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(01)02264-X     Document Type: Review

References (67)

1. The discovery of immunostimulatory DNA sequence
2. DNA vaccines: Immunology, application, and optimization
3. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity
4. In vitro augmentation of natural killer cell activity and production of interferon-α/β and -γ with deoxyribonucleic acid fraction from Mycobacterium bovis BCG
5. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
6. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells
7. CpG motifs in bacterial DNA trigger direct B-cell activation
8. The role of CpG motifs in immunostimulation and gene therapy
9. Mechanisms of immune stimulation by bacterial DNA
10. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1
11. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice
12. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons
13. A Toll-like receptor recognizes bacterial DNA
14. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice
15. Signal transduction pathways activated by CpG-DNA
16. Signal transduction induced by immunostimulatory CpG DNA
17. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA
18. Oligodeoxyribonucleotides with 5′-ACGT-3′ or 5′-TCGA-3′ sequence induce production of interferons
19. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
20. Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells
21. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition
22. Influence of backbone chemistry on immune activation by synthetic oligonucleotides
23. Phosphorothioate backbone modification modulates macrophage activation by CpG DNA
24. Stereo-enriched phosphorothioate oligodeoxynucleotides: Synthesis, biophysical and biological properties
25. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs
26. Antimetastatic effect of CpG DNA mediated by type I IFN
27. Cytokines in innate and adaptive immunity
28. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies
29. Antisense therapeutics: Is it as simple as complementary base recognition?
30. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)
31. Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine
32. Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization
33. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans
34. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice
35. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgns monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)
36. Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus
37. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif
38. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis
39. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis
40. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant
41. Interleukin-12- and γ interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice
42. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens
43. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria
44. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines
45. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity
46. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs
47. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo
48. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients
49. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity
50. The influence of CpG motifs on a protein or DNA-based Th2-type immune response against major pollen allergens Bet v 1a, Phl p 2 and Escherichia coli-derived beta-galactosidase
51. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma
52. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator
53. Recent developments in adjuvants for vaccines against infectious diseases
54. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells
55. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes
56. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides
57. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles
58. Antisense and/or immunostimulatory oligonucleotide therapeutics
59. Activation of the innate immune system by CpG oligodeoxynucleotides: Immunoprotective activity and safety
60. Effect of different chemically modified oligodeoxynucleotides on immune stimulation
61. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: Structure-immunostimulatory activity relationships
62. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases
63. Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity
64. Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxymucleoside
65. Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages
66. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity
67. Therapeutic potential of synthetic CpG DNA - Current status and future directions